Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar 7:2:8.
doi: 10.1186/2110-5820-2-8.

Cardiac biomarkers in the intensive care unit

Anthony S McLean  1 , Stephen J Huang
Affiliations

Cardiac biomarkers in the intensive care unit

Anthony S McLean et al. Ann Intensive Care. .

Abstract

Cardiac biomarkers (CB) were first developed for assisting the diagnosis of cardiac events, especially acute myocardial infarction. The discoveries of other CB, the better understanding of cardiac disease process and the advancement in detection technology has pushed the applications of CB beyond the 'diagnosis' boundary. Not only the measurements of CB are more sensitive, the applications have now covered staging of cardiac disease, timing of cardiac events and prognostication. Further, CB have made their way to the intensive care setting where their uses are not just confined to cardiac related areas. With the better understanding of the CB properties, CB can now help detecting various acute processes such as pulmonary embolism, sepsis-related myocardial depression, acute heart failure, renal failure and acute lung injury. This article discusses the properties and the uses of common CB, with special reference to the intensive care setting. The potential utility of "multimarkers" approach and microRNA as the future CB are also briefly discussed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The development of cardiac biomarkers. ADM, adrenomedullin; BNP, B-type natriuretic peptide; CAM, cell adhesion molecule; CK-MB, creatine kinase-MB; CRP, C-reactive protein; cTn, cardiac troponin; H-FABP, human fatty-acid binding protein; HSP, heat shock protein; IL, interleukin; IMA, ischemia-modified albumin; INFγ, interferon γ; LP-LPA2, lipoprotein-associated phospholipase A2; PAPP, pregnancy-associated plasma protein; ROS, reactive oxygen species; sCD40L, soluble CD40 ligand.
Figure 2
Figure 2
Evolution of cardiac dysfunction and the associated changes in cardiac biomarkers. (see legend to Figure 1 for abbreviations).
Figure 3
Figure 3
Contributors to circulating BNP level.
See this image and copyright information in PMC

References

    1. Blankesteijn W, Cremmers E, Lutgens E, Cleutjens J, Daemen M, Smits J. Dynamics of cardiac wound healing following myocardial infarction: observations in genetically altered mice. Acta Physiol Scand. 2001;173:75–82. - PubMed
    1. Liao Y-H, Cheng X. Autoimmunity in myocardial infarction. Int J Cardiol. 2006;112:21–26. - PubMed
    1. Caforio A. Ciculating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance. Eur J Heart Failure. 2002;4(4):411–417. - PubMed
    1. Cooper L. The heat is off: immunosuprression for myocarditis revisited. Eur Heart J. 2009;30:1936–1939. - PubMed
    1. Packard R, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discover and risk prediction. Clin Chem. 2008;54:24–38. - PubMed